+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Update upon the infection risk in patients receiving TNF alpha inhibitors



Update upon the infection risk in patients receiving TNF alpha inhibitors



Expert Opinion on Drug Safety 2019



TNF-α inhibitors can be administered either as monotherapy or in combination with other anti-inflammatory drugs or DMARDs in the treatment of chronic immune-mediated diseases. Areas covered: Patients receiving TNF-α inhibitors are at high risk of infections. An update is made on the risk of infection in patients receiving TNF-α inhibitors and the strategies for mitigating against the development of these serious adverse events. Expert opinion: Infliximab than etanercept appears to be responsible for the increased risk of infections. Re-activation of latent tuberculosis infection and the overall risk of opportunistic infections should be considered before beginning a course of TNF-α inhibitors. A careful medical history, Mantoux test/quantiferon-TB Gold In-tube Test and chest-X-ray should always be performed before starting TNF-α inhibitors. Particular attention should be paid to risk factors for Pneumocystis jirovecii infection. Hepatitis B and C virological follow-up should be considered during TNF-α inhibitors treatment. Finally, appropriate vaccinations for influenza, S. pneumoniae and HBV should be administered to decrease the risk of infection, and patients who are at high risk of herpes zoster reactivation would benefit from a second vaccination in adulthood.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066446425

Download citation: RISBibTeXText

PMID: 30704314

DOI: 10.1080/14740338.2019.1577817


Related references

Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs. Arthritis and Rheumatology 68(1): 67-76, 2016

Travel in patients receiving TNF-alpha inhibitors. Travel Medicine and Infectious Disease 3(2): 105-109, 2007

Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. Annals of the Rheumatic Diseases 74(6): 1065-1071, 2015

Management of cardiovascular risk in patients receiving calcineurin inhibitors--a case report. Nephrology, Dialysis, Transplantation 21 Suppl 3: Iii30-3, 2006

Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors. Thrombosis and Haemostasis 104(3): 626-632, 2010

Decreased incidence of disseminated MAC infection in 689 AIDS patients receiving antiretroviral treatment with protease inhibitors. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 37: 248, 1997

Risk of small intestinal bacterial overgrowth in patients receiving proton pump inhibitors versus proton pump inhibitors plus prokinetics. Jgh Open 2(2): 47-53, 2018

Risk of infection during treatment with tumor necrosis factor-alpha inhibitors. Zeitschrift für Rheumatologie 65(1): 24-8, 30-1, 2006

Metabolic and vascular factors contribute to increased cardiovascular risk in HIV+ patients receiving protease inhibitors. Diabetologia 44(Supplement 1): A313, 2001

Contribution of genetic amplification by PCR for the diagnosis of Helicobacter pylori infection in patients receiving proton pump inhibitors. United European Gastroenterology Journal 6(8): 1267-1273, 2018

Increased risk of benign prostatic hyperplasia-related surgery in patients using alpha-blockers compared to 5-alpha reductase inhibitors. European Urology Supplements 2(1): 160, 2003

Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of Psoriasis. JAMA Dermatology 2019, 2019

Increased risk of ischemic and hemorrhagic events among black patients receiving oral GP IIb/IIIa inhibitors 1st and 2nd SYMPHONY Trials. Circulation 104(17 Supplement): II 779, October 23, 2001

Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunology, ImmunoTherapy 2019, 2019

Risk of Clostridium difficile infection in hospitalized patients receiving metronidazole for a non-C difficile infection. Clinical Gastroenterology and Hepatology 12(11): 1856-1861, 2015